Cambridge Investment Research Advisors Inc. Buys 17,500 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Cambridge Investment Research Advisors Inc. lifted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 168.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,867 shares of the biotechnology company’s stock after acquiring an additional 17,500 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Heron Therapeutics were worth $61,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in HRTX. RFP Financial Group LLC acquired a new position in Heron Therapeutics during the first quarter worth $26,000. Nicolet Advisory Services LLC acquired a new stake in Heron Therapeutics in the fourth quarter valued at $25,000. Argent Advisors Inc. acquired a new stake in Heron Therapeutics in the fourth quarter valued at $31,000. Focus Partners Wealth acquired a new stake in Heron Therapeutics in the fourth quarter valued at $31,000. Finally, State of Wyoming lifted its stake in Heron Therapeutics by 573.5% in the fourth quarter. State of Wyoming now owns 29,736 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 25,321 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HRTX. Wall Street Zen upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. HC Wainwright began coverage on shares of Heron Therapeutics in a research note on Monday, June 9th. They set a “buy” rating and a $6.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, April 11th.

Heron Therapeutics Stock Down 3.8%

Shares of Heron Therapeutics stock opened at $2.04 on Wednesday. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.73. The company has a 50-day simple moving average of $2.03 and a two-hundred day simple moving average of $1.98. The stock has a market capitalization of $311.22 million, a price-to-earnings ratio of -34.00 and a beta of 1.18.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. On average, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.